Cardiovascular

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology

1.5 Credits / Cardiology, Rare Diseases

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

More News

October 13th 2017

Countywide Physician Organization Learning Collaborative and Changes in Hospitalization Rates

Brent D. Fulton, PhD, MBA Susan L. Ivey, MD, MHSA Hector P. Rodriguez, PhD, MPH Stephen M. Shortell, PhD, MPH, MBA

The University of Best Practices physician organization learning collaborative in San Diego County was associated with lower hospitalization rates for heart attacks.

October 12th 2017

Higher Physical Activity Lowers Risk of Mortality and Cardiovascular Disease

Jaime Rosenberg

A study has found that both recreational and non-recreational activity reduces the risk of mortality and cardiovascular disease, regardless of the country's economic status.

October 11th 2017

Lower LDL Cholesterol Associated With Higher Mortality in American Indians

Excessively low levels of low-density lipoprotein cholesterol and triglycerides is associated with a higher all-cause mortality among American Indians, according to a new study published online ahead of print in Journal of Diabetes and Its Complications.

October 3rd 2017

Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments

Current drugs for pulmonary hypertension treat 3 pathways, but currently there aren't any new drugs to treat different pathways, although there likely will be some in the future, said Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.

October 1st 2017

Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol

There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.

September 18th 2017

Early Trauma, Depression, and the Need for Social Connection

Experts said that the frequency and quality of social relationships have a greater effect on mortality than obesity or drinking alcohol, and this commands attention from health systems.

September 15th 2017

5 Facts About Air Pollution's Impact on Health

In the wake of Hurricane Harvey, Houston is expected to face a host of health challenges, including air pollution. Here are 5 facts about how air pollution affects people’s health.

September 13th 2017

Statin Drug Use in COPD Patients Linked to Mortality Reductions

The use of statin drugs in patients with chronic obstructive pulmonary disease is associated with benefits including decreased lung-related and all-cause mortality, according to a research.

September 7th 2017

Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution

Researchers have known for years: what happens to mom in pregnancy affects the baby. That holds true with prenatal exposure to air pollution, which has lingering cardiovascular effects, such as birth defects and a higher risk of obesity, explained Jeanette Stingone, PhD, of Mount Sinai Health System.

September 1st 2017

This Week in Managed Care: September 1, 2017

This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.

August 31st 2017

Liraglutide Improves Renal Outcomes in Type 2 Diabetes Patients With CV Risk

The study finds that the GLP-1 receptor agonist can slow progression of kidney disease, one of the most costly and debilitating complications of type 2 diabetes.

August 30th 2017

Study in Lancet Challenges Diet Wisdom About Fat, Vegetables

The findings will likely add to the controversy over the US dietary guidelines. Lobbyists for grain interests have long been accused of having undue influence in food policy, especially over the now-discarded "food pyramid."

August 29th 2017

Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.

August 28th 2017

Dr Deepak Bhatt Highlights COMPASS Trial Results

The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events that it was stopped early, explained Deepak Bhatt, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.

August 27th 2017

An Eye on Cardiovascular Prevention: Begin in Childhood, Identify All Risk Factors

For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

August 27th 2017

COMPASS: Rivaroxaban Plus Aspirin Protects Against Heart Attack, Stroke

Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

August 26th 2017

Dr Steven Nissen Outlines New Treatments in Cardiovascular Medicine

Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.

August 25th 2017

Liraglutide Gains New Indication for Reducing CV Event Risk

Christina Mattina

Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.

August 14th 2017

Study Highlights Mechanism Connecting Diabetes, Elevated Cholesterol

The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.

August 8th 2017

Review: Expanded Therapy Plus Lifestyle Change Needed to Reduce CV Risk in Type 2 Diabetes

The review reports that fewer than 50% of patients with diabetes are being treated according guidelines to prevent a cardiovascular event.

August 6th 2017

Study Examines Inpatient Rehabilitation for Patients With Marfan Syndrome

Patients with congenital heart defects, such as Marfan syndrome (MFS), are experiencing longer life expectancies due to new advances in medicine-resulting in a greater need for medical rehabilitation.

August 1st 2017

Gastric Bypass Sharply Lowers Death Risk for People With Diabetes, Study Finds

The reduced mortality risk was not seen in patients who did not have diabetes before surgery. But in those who did, the results were dramatic.

July 30th 2017

Continued Statin Use Following Adverse Reaction May Reduce Incidence of Death and CVD Events

Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.

July 25th 2017

Study Finds ACOs Have No Meaningful Impact on Medication Use or Adherence

Many accountable care organizations participating in the Medicare Shared Savings Program focus on disease control and medication use, but a new study published in JAMA Cardiology has found that the programs have not made any meaningful changes in medication use or adherence.

July 20th 2017

From Unexpected CV Benefits to Potential in Heart Failure: Insights and Outlook for SGLT2 Inhibitors

Coverage from the first of 3 Peer Exchangeâ„¢ discussions from the Diabetes Stakeholders Summit.

July 16th 2017

Link Found Between Childhood Cardiovascular Risk Factors and Future Lower Cognition

There is an association between the presence of cardiovascular risk factors in adolescence and a lower cognition later in life, regardless of the exposure experienced during adulthood.

July 13th 2017

Study Suggests New Vaccine Can Lower Cholesterol, Immunize Against CVD

A new vaccine may be able to reduce low-density lipoprotein (LDL) cholesterol and, therefore, protect people against the risk of cardiovascular disease.

July 8th 2017

Excess Cardiovascular Risk in RA Patients Has Declined Since 2000, Study Finds

New results from a meta-analysis reveal a decrease in the excess risk of cardiovascular events in patients with rheumatoid arthritis (RA) since the start of the 21st century.

June 21st 2017

FDA Panel Gives Liraglutide Nod for CV Indication

Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.

June 16th 2017

5 Takeaways From ADA 2017